Welcome to Cardiology Today – Recorded January 12, 2026. This episode summarizes 5 key cardiology studies on topics like pig model and vascular inflammation. Key takeaway: Neratinib Protects Against Vascular Inflammation..

Article Links:

Article 1: The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)

Article 2: Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. (Heart rhythm)

Article 3: Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). (The American journal of cardiology)

Article 4: Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis. (Circulation research)

Article 5: Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension. (American journal of hypertension)

Full episode page: https://podcast.explainheart.com/podcast/neratinib-protects-against-vascular-inflammation-01-12-26/

Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520801

Summary: Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.

Journal: Heart rhythm

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520933

Summary: The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.

Journal: The American journal of cardiology

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41520805

Summary: Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.

Journal: Circulation research

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41510568

Summary: Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.

Journal: American journal of hypertension

PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41513752

Summary: Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure.

Today’s date is January 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.

Article number one. The association between glucagon-like peptide 1 receptor agonists therapy and outcomes after heart transplant. Glucagon-like peptide 1 receptor agonists demonstrate established survival benefits and cardioprotective effects in patients with diabetes and heart failure. However, the association of glucagon-like peptide 1 receptor agonist use with mortality and morbidity specifically in heart transplant recipients has not been previously determined. This retrospective study assessed glucagon-like peptide 1 receptor agonist use among adult heart transplant patients from three Mayo Clinic sites who survived at least one month post-transplantation.

Article number two. Monopolar biphasic focal pulsed field ablation directly at the atrioventricular junction and from within the non-coronary cusp: The PFA-CONDUCT study. The PFA-CONDUCT study evaluated the application of monopolar biphasic focal pulsed field ablation in proximity to the atrioventricular node and from within the aortic non-coronary cusp. In pig models, direct ablation was performed at the atrioventricular junction in three animals and indirect application occurred from the non-coronary cusp in five animals, followed by macroscopic and histological analyses. The investigation further included five human patients undergoing a pace-and-ablate strategy, demonstrating its application in a clinical context.

Article number three. Clinical Assessment of Sequential Slow and Ultra-Slow Thrombolysis Approaches for Stuck Prosthetic Valve Thrombosis as a Novel Dose-Adjusted Regimen Analysis (The Multicenter CASSANDRA Study). Thrombolytic therapy utilizing low-dose, slow, and ultra-slow infusions of tissue-type plasminogen activator is an established first-line treatment for prosthetic valve thrombosis. Prosthetic valve thrombosis involving stuck valves represents a distinct clinical entity that demands tailored management. The multicenter CASSANDRA study enrolled 52 patients with prosthetic valve thrombosis and stuck valves to evaluate the effectiveness and safety of sequentially combining different thrombolytic therapy regimens for this specific condition.

Article number four. Neratinib, a Clinical Drug Against Breast Cancer, Protects Against Vascular Inflammation and Atherosclerosis. Neratinib, a clinical drug primarily used against breast cancer, provides protection against vascular inflammation and atherosclerosis. Atherosclerosis begins with endothelial dysfunction and cholesterol retention, followed by a chronic inflammatory response that current low-density lipoprotein-cholesterol lowering therapies often do not fully address. This drug offers a novel therapeutic approach to mitigate the persistent residual inflammatory risk observed in patients with atherosclerotic cardiovascular diseases.

Article number five. Cardiovascular and Kidney Events Associated with Visit-to-Visit Blood Pressure Variability among Young Adults with Hypertension. Visit-to-visit blood pressure variability and cumulative blood pressure exposure are associated with increased risks of cardiorenal events. This study specifically investigated these associations in young adults aged 18 to 39 years diagnosed with stage one or stage two hypertension. Researchers identified these adults from a large U. S. integrated healthcare system between 2009 and 2019, utilizing the coefficient of variation for blood pressure variability and time-weighted values for cumulative blood pressure exposure.

Thank you for listening. Don’t forget to subscribe.

pig model, vascular inflammation, blood pressure variability, tissue-type plasminogen activator, low-density lipoprotein-cholesterol, glucagon-like peptide 1 receptor agonists, heart transplant, breast cancer drug, heart failure, atherosclerosis, prosthetic valve thrombosis, sequential regimens, cardiorenal events, cumulative blood pressure exposure, non-coronary cusp, focal pulsed field ablation, young adults, hypertension, pace-and-ablate, atrioventricular node, mortality, thrombolytic therapy, stuck valves, diabetes, neratinib.

Concise summaries of cardiovascular research for professionals.

Subscribe • Share • Follow

The post Neratinib Protects Against Vascular Inflammation. 01/12/26 first appeared on Cardiology Today.